Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82)

BACKGROUND: Several cancer immunotherapies that target the PD-L1/PD-1 pathway show promising clinical activity in patients with hepatocellular carcinoma (HCC). However, the standard of care in first-line treatment with atezolizumab (anti-PD-L1 therapy) in combination with bevacizumab is associated w...

Descripción completa

Detalles Bibliográficos
Autores principales: Vienot, Angélique, Jacquin, Marion, Rebucci-Peixoto, Magali, Pureur, Dimitri, Ghiringhelli, François, Assenat, Eric, Hammel, Pascal, Rosmorduc, Olivier, Stouvenot, Morgane, Allaire, Manon, Bouattour, Mohamed, Regnault, Hélène, Fratte, Serge, Raymond, Eric, Soularue, Emilie, Husson-Wetzel, Stéphanie, Di Martino, Vincent, Muller, Allison, Clairet, Anne-Laure, Fagnoni-Legat, Christine, Adotevi, Olivier, Meurisse, Aurélia, Vernerey, Dewi, Borg, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387199/
https://www.ncbi.nlm.nih.gov/pubmed/37516867
http://dx.doi.org/10.1186/s12885-023-11065-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387199/
https://www.ncbi.nlm.nih.gov/pubmed/37516867
http://dx.doi.org/10.1186/s12885-023-11065-0

Ejemplares similares